Arteriosclerosis Obliterans
Conditions
Keywords
Arteriosclerosis Obliterans, Atherosclerotic Occlusive Disease of the Lower Extremities, Intermittent Claudication
Brief summary
A phase II,randomized,double-blind,multi-doses,positive drug parallel controlled,multi-center clinical trial to evaluate initially the efficacy and safety of alprostadil liposomes for injection in the treatment of atherosclerotic occlusive disease of the lower extremities.
Detailed description
This is a phase 2 dose-finding study evaluating initially the efficacy and safety of alprostadil liposomes for injection in the treatment of atherosclerotic occlusive disease of the lower extremities at different dose strengths.The total duration of subject participation will be approximately 5 weeks,consisting of a 2-week run-in period,3-week treatment and safety follow-up period. Subjects will sign the informed consent form(ICF) at a screening visit and will be assigned a subject identifier.Subjects meeting all inclusion/exclusion criteria and who have successfully completed all protocol procedures at screening will enter the 2-week run-in.Following the 2-week run-in period,eligible subjects will be randomized(1:1:1:1) to one of the following double-blind treatment groups: Group A : Alprostadil Liposomes for Injection at low dose:20ug,once a day(QD); Group B : Alprostadil Liposomes for Injection at medium dose:40ug,QD Group C : Alprostadil Liposomes for Injection at high dose:60ug,QD Group D(Positive Control Group) : Alprostadil Injection:10ug,QD All treatments will be delivered by intravenously guttae.A subject will be consider to have completed the study when they have completed all phase of the study including run-in,randomization,the randomized treatment and efficacy and safety follow-up phase.
Interventions
3 doses of Alprostadil Liposomes for Injection are 20ug/q.d,40ug/q.d,60ug/q.d.All groups will be continuous administration for 3 weeks.
Alprostadil Injection(the positive control group):10ug/q.d,continuous administration for 3 weeks.
Sponsors
Guangzhou Yipinhong Pharmaceutical CO.,LTD
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* An established clinical history of Atherosclerotic Occlusive Disease of the Lower Extremities in accordance with the definition by Chinese Medical Association(2015). * Age\>40 * Atherosclerotic Occlusive Disease of the Lower Extremities diagnosis * Arterial ischemia of the lower extremities pulsation has been weakened or disappeared. * Ankle brachial index(ABI) less than or equal to 0.9 * Diagnosis of artery stenosis or occlusion with imaging tests,including Doppler ultrasonography,CT angiogram(CTA),magnetic resonance angiography (MRA) or digital subtraction angiography(DSA) within 1 month prior to Screening. * Fontaine stage classification:Stage II * Distance of asymptomatic disease and claudication between 50m to 800m(The treadmill setting:pace at 3 km/h,incline at 12%).Subjects have intermittent claudication twice within 1 week prior to enrollment visit(Baseline is defined as the first measurement.Change from baseline in P-values less than or equal to 25%). * Age:80 years old or younger. * Intermittent claudication has been in stable condition in the last 6 months.And there was no history of exacerbations within 3 months prior to enrollment visit. * Informed Consent:A signed and dated written informed consent prior to study participation.
Exclusion criteria
* Subjects who have cardiac disease including caradiac failure,arrhythmias,coronary disease,mitral or aortic stenosis.Subjects with a recent history of myocardial infarction within the past 6 months are to be excluded. * Subjects who have pneumonedema,pulmonary infiltrates,interstitial pneumonia,severe chronic obstructive airway disorders or respiratory insufficiency confirmed by clinical examination. * Liver:Subjects with abnormal liver function tests defined as aspartate aminotransferase(AST) or alanine aminotransferase(ALT) greater than equal to 1.5 times upper limit of normal,as well as a diagnosis of primary liver disease will be excluded. * Renal:Subjects with abnormal kidney function tests defined as Creatinine clearance rate(SCr) greater than or equal to upper limit of normal. * Clinically Uncontrolled Hypertension:Subjects who have clinically significant uncontrolled hypertension(Systolic blood pressure:greater than or equal to 180mmHg;Or diastolic blood pressure:greater than or equal to 110mmHg). * Ankle systolic pressure is less than or equal to 50mmHg. * Subjects with affected limbs surgery or endovascular treatment within 3 months prior to Screening.Subjects who received Prostanoids within the past 1 week are to be excluded. * Subjects who received walking rehabilitation training successfully within the past 6 months. * Subjects with a diagnosis of other diseases such as lower limb joint disorder,spinal lesions,neuropathy,serious lung and heart conditions which may impact intermittent claudication will be excluded. * Subjects who have inflammation of the vascular disease including Takayasu's arteritis,edema perivascular. * Subjects with active peptic ulcerease or bleeding tendency will be excluded. * Glaucoma:Subjects with a diagnosis of glaucoma or high intraocular pressure will be excluded. * Subjects who are medically unable to withhold their vasodilator including naftidrofuryl,pentoxy,buflomedil or cilostazol will be excluded. * Subjects who received any powerful analgesic within 1 month perior to Screening. * Subjects with a history of psychiatric disease or Alzheimer's Disease. * Cancer:Subjects with a diagnosis of cancer will be excluded. * Drug Allergy:Subjects who have a history of any componet of Alprostadil Injection. * Previous Participation:Subjects who were previously enrolled in any clinical trial within 1 month period to Screening. * Pregnancy:Women who are pregnant or lactating or women of childbearing potential who are not using an acceptable method of contraception. * Subjects,who in the opinion of the Investigator,will not be fit for this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in distance of asymptomatic disease and claudication after 3 weeks of treatment. | After 3 weeks of treatment | Unit of distance of asymptomatic disease and claudication:meters |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in maximun distance of claudication after 3 weeks of treatment. | After 3 weeks of treatment | Unit of maximun distance of claudication :meters |
| Change from baseline in distance of asymptomatic disease and claudication and in maximum distance of claudication after 2 weeks of treatment. | After 2 weeks of treatment | Unit of distance of asymptomatic disease and claudication:meters |
| The proportion of patients to treatment failure. | After 3 weeks of treatment | The treatment failure is defined as arteriosclerosis obliterans(ASO) exacerbation that has necessary to change chemotherapy or have interventional operation. |
| Incidence of Adverse Events(AEs) | over 3 weeks of treatment | The safety endpoints for this study include: 1. AEs 2. Vital Sign Measurements 3. Physical examination 4. Clinical Laboratory Evaluations |
Countries
China
Contacts
Primary ContactYongquan Gu
Outcome results
None listed